AMRI will continue to supply an Aminobisamide Hydrochloride (ABA), an intermediate material used in diagnostic imaging agents, to GE Healthcare, under the signed long term supply agreement which extends till 31 December 2016.
Under the agreement, AMRI will continue to produce ABA at its large scale manufacturing subsidiary in Rensselaer, New York, US.
AMRI chairman, CEO and president Thomas D'Ambra said the extension of partnership demonstrates the company's commitment to performance, quality and customer satisfaction.
"The ABA product relationship with GE Healthcare has been an important one for AMRI since acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement," D'Ambra added.
"We continue to be pleased with the progress that we are making in our Large Scale Manufacturing business segment, the largest component of which is our Rensselaer site.
"We are adding new customers and new products at this facility, along with continuing the long-term relationships, like GE Healthcare, that have formed the basis of our revenue stream."
